Dow Dips 1%; Mustang Bio Shares Spike Higher

Written by Emily J. Thompson, Senior Investment Analyst

APGE+0.02%

LGPS-3.99%

ARTL+3.01%

Source: Benzinga

Updated: Jul 07 2025

0mins

Source: Benzinga

U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones dropping over 400 points and the S&P 500 and NASDAQ also experiencing losses; however, industrial shares saw a slight increase.
Notable Company Updates: Mustang Bio's shares surged 319% after receiving FDA Orphan Drug Designation, while Jasper Therapeutics' shares plummeted 51% following disappointing study results.

APGE

$80.77+Infinity%1D

Analyst Views on APGE

Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 95.00 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Analyst Rating

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 80.750

Low

70.00

Averages

95.00

High

115.00

Current: 80.750

Low

70.00

Averages

95.00

High

115.00

Craig-Hallum

Buy

maintain

$109 -> $116

Al Analysis

2026-01-07

Reason

Craig-Hallum

Price Target

$109 -> $116

Al Analysis

2026-01-07

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Apogee Therapeutics to $116 from $109 and keeps a Buy rating on the shares. Apogee comes out swinging in 2026 with encouraging Phase 1b asthma data for zumilokibart that, in the firm's view, validate depth/durability and supports a pipeline-in-a-product narrative with a plausible path to every 3-6-month dosing across multiple inflammation and immunology indications. Management plans to announce additional asthma program details later this year and additional Phase 1b data at a medical meeting, Craig-Hallum adds. The firm would lean into POC in asthma and durability as the key takeaway from this data ahead of three atopic dermatitis datasets in 2026 that should further define dose response, durability, and differentiation.

Wolfe Research

Peer Perform

initiated

2026-01-07

Reason

Wolfe Research

Price Target

2026-01-07

initiated

Peer Perform

Reason

Wolfe Research initiated coverage of Apogee Therapeutics with a Peer Perform rating and no price target. While asthma appeared to have been a minor catalyst, any future success could have long-term implications, the analyst tells investors. However, with that said, "convenience euphoria has blasted the stock to all-time highs," adds the analyst, who foresees two negative catalysts in the first half of the year, followed by a high-conviction positive catalyst in the second half.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APGE

Unlock Now

Stifel

Buy

maintain

$95 -> $133

2026-01-06

Reason

Stifel

Price Target

$95 -> $133

2026-01-06

maintain

Buy

Reason

Stifel raised the firm's price target on Apogee Therapeutics to $133 from $95 and keeps a Buy rating on the shares following positive Phase 1b asthma data for zumilokibart. Apogee's Phase 1b data "represents clear evidence of activity" that should support accrual of meaningful credit in the stock and further support for the pipeline-in-a product thesis, the analyst tells investors.

BTIG

Buy

maintain

$128 -> $137

2026-01-06

Reason

BTIG

Price Target

$128 -> $137

2026-01-06

maintain

Buy

Reason

BTIG raised the firm's price target on Apogee Therapeutics to $137 from $128 and keeps a Buy rating on the shares. A key goal for zumilokibart is to emerge as the first IL-13 inhibitor with dual asthma and atopic dermatitis labeling, and the firm sees high odds of that materializing following today's results. BTIG is increasing its probability of success of zumilokibart in asthma to 85% from 60%. Phase 1b results reported today in mild-to-moderate asthma land well into BTIG's blue sky scenario, it adds.

About APGE

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.